GH RESEARCH PLC
GHRSNASDAQTrading Snapshot
- Day Range
- $20.77 – $22.00
- 52-Week Range
- $12.04 – $31.44
- Volume (shares)
- 345,100
- Avg Volume (shares)
- —
- Shares Outstanding
- 68.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.99
- Dividend Yield
- —
- Dilution (1yr)
- +19.2%
GH RESEARCH PLC
GHRS
StockOtter · stockotter.spaceAbout GH RESEARCH PLC
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
GH Research remains significantly undervalued due to the large unmet need in treatment-resistant depression and GH001's potential efficacy. While early data appears promising, and Eli Lilly's acquisition of AtaiBeckley v
GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of GH Research PLC (NASDAQ: GHRS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One res
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its IND for GH001, posit
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a results in postpartum depr